查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肌肉減少症市場－全球及區域分析：按治療層級、給藥途徑、通路和地區分類的分析和預測（2025-2035 年）
市場調查報告書
商品編碼
1856055

肌肉減少症市場－全球及區域分析：按治療層級、給藥途徑、通路和地區分類的分析和預測（2025-2035 年）

Sarcopenia Market - A Global and Regional Analysis: Focus on Treatment Class, Route of Administration, Distribution Channel, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

老年人口的快速成長顯著提高了全球肌肉萎縮性疾病的盛行率，從而推動了全球肌肉減少症市場的發展。隨著60歲及以上人口數量的持續成長，尤其是在已開發國家和新興國家，對肌肉減少症診斷和治療的需求正在迅速擴大。此外，握力評估、步速測試和雙能量X光檢測法（DXA）等診斷工具的進步，提高了早期發現肌肉減少症的能力。

臨床意識的提高使得肌肉減少症的檢出率更高，有助於及時介入。此外，我們見證了治療藥物創新的顯著進展，尤其是在荷爾蒙治療（如睪固酮替代療法）和靶向合成代謝肌肉通路生物製藥（如肌肉生長抑制素抑制劑和選擇性雄激素受體調變器(SARMs)）的研發方面。這些進展為更有效、更有針對性地管理老年族群的肌肉減少症提供了充滿希望的途徑。

阻礙市場成長的主要挑戰之一是缺乏國際統一的診斷標準。診斷標準的差異，例如歐洲老年醫學會（EWGSOP）、亞洲老年醫學會（AWGS）和其他區域組織提出的標準，導致肌肉減少症的識別和分類不一致，阻礙了大規模臨床研究、監管核准和治療標準化。此外，肌肉減少症相關療法（尤其是營養補充劑和非藥物療法）的保險覆蓋範圍和報銷有限，限制了患者的就醫途徑，也降低了醫療機構採用這些療法的動機。

全球肌肉減少症市場在新興醫療保健趨勢和技術進步的推動下，蘊藏著巨大的發展機會。快速的都市化進程、不斷完善的醫療基礎設施以及新興國家（尤其是亞太和拉丁美洲地區）日益成長的老齡人口，正為市場擴張開闢新的途徑。這些地區正擴大採用各種解決方案來預防和治療與老齡化相關的疾病，從而為肌肉減少症干預創造了巨大的潛力。在技​​術創新的前沿，一些公司正在探索再生醫學和幹細胞治療方法，例如MyoPax GmbH和遠端醫療 Biotechnologies等公司開發的療法，旨在從細胞層面恢復肌肉功能並逆轉肌肉退化。此外，穿戴式裝置、遠距醫療平台和人工智慧肌肉監測應用程式等數位健康工具的整合，正在提升早期診斷、患者參與度和長期疾病管理水平。這些進步正在共同再形成肌肉減少症的格局，為全球老齡人口提供個人化、便利且技術驅動的醫療服務。

市場分類

細分 1：依治療層級

  • 營養補充品
    • 蛋白質補充品（乳清蛋白、酪蛋白、膠原蛋白）
    • 胺基酸補充劑（亮氨酸、HMB、肌酸）
    • 維生素D和鈣補充劑
    • 維生素B12和葉酸補充劑
    • Omega-3脂肪酸補充劑
  • 製藥
    • 荷爾蒙補充療法（睪酮及類似物質）
    • 血管緊張素轉換酶抑制劑/血管收縮素II受體阻斷劑
    • 其他（生長激素促分泌劑）
  • 聯合治療

細分 2：依給藥途徑

  • 口服
  • 腸外
  • 經皮/局部

細分3：按分銷管道

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 其他

細分 4：按地區

  • 北美洲
  • 歐洲
  • 亞太地區

肌肉減少症市場正經歷著變革性的趨勢，這些趨勢正在重塑研究、開發和交付格局。其中一個顯著的趨勢是人工智慧在藥物研發中的應用日益廣泛，企業利用先進的演算法來識別新的治療靶點，並加速開發針對肌肉萎縮的精準療法。這種技術整合縮短了藥物上市時間，並實現了更具針對性和成本效益的藥物研發。同時，聯合治療也越來越受歡迎，它將藥物與營養補充劑和物理療法相結合，以期在改善肌肉質量和功能方面產生協同效應。這種多模態策略正在獲得臨床支持，並改善患者的治療效果。

本報告檢視了全球肌少症市場，並總結了關鍵趨勢、市場影響因素分析、法律規範、市場規模趨勢和預測、按各個細分市場和主要國家/地區進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

第1章 全球肌肉減少症市場：產業分析

  • 市場概覽與生態系統
  • 價值鏈分析
  • 主要市場趨勢
    • 影響分析
  • 監管狀態
  • 市場動態
    • 概述
    • 市場促進因素
    • 市場限制
    • 市場機遇

2. 全球肌肉減少症市場依治療層級

  • 營養補充品
    • 蛋白質補充品（乳清蛋白、酪蛋白、膠原蛋白）
    • 胺基酸補充劑（亮氨酸、HMB、肌酸）
    • 維生素D和鈣補充劑
    • 維生素B12和葉酸補充劑
    • Omega-3脂肪酸補充劑
  • 製藥
    • 荷爾蒙補充療法（睪酮及類似物質）
    • 血管緊張素轉換酶抑制劑/血管收縮素II受體阻斷劑
    • 其他（生長激素促分泌劑）
  • 聯合治療

3. 全球肌肉減少症市場（依給藥途徑分類）

  • 口服
  • 腸外
  • 經皮/局部

4. 全球肌肉減少症市場按分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 其他

5. 全球肌少症市場（按地區分類）

  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區
    • 市場動態
    • 市場規模及預測
    • 市場規模及預測：依國家分類

6. 全球肌肉減少症市場的競爭格局與公司概況

  • 競爭格局
  • 公司簡介
    • Nestle Health Science
    • Abbott Laboratories
    • Bayer AG
    • Sanofi SA
    • Novartis AG
    • Eli Lilly and Company
    • MyoPax GmbH
    • Amgen Inc.
    • Pfizer Inc
    • GlaxoSmithKline plc
    • 其他

第7章調查方法

Product Code: BHL3353SA

Global Sarcopenia Market, Analysis and Forecast: 2025-2035

Sarcopenia is a progressive musculoskeletal disorder characterized by the loss of skeletal muscle mass, strength, and function, predominantly affecting older adults. It is clinically diagnosed based on the presence of three primary indicators: reduced muscle strength, diminished muscle quantity or quality, and impaired physical performance. This condition not only limits an individual's ability to perform daily tasks but also serves as a strong predictor of adverse postoperative outcomes, including higher rates of complications, morbidity, and mortality. Moreover, sarcopenia significantly increases the risk of falls and fractures, particularly in aging populations, and contributes to loss of independence in individuals over 90 years old. Due to its rising clinical significance, sarcopenia has been officially classified with a unique ICD-10 code to aid in diagnosis and differentiation from other muscle-wasting conditions.

The etiology of sarcopenia is multifactorial, with aging being the most prominent contributing factor. Globally, the prevalence is estimated at approximately 10% in individuals aged 60 and older and can reach up to 50% or higher in those aged 80 and above. These estimates vary widely due to differing diagnostic methods and heterogeneous populations across studies. While sarcopenia affects both men and women, its progression is closely tied to age-related biological changes, sedentary lifestyles, poor nutrition, and comorbidities. As the global population ages, sarcopenia is emerging as a critical public health concern, underscoring the urgent need for standardized diagnostic criteria and effective therapeutic strategies. The global Sarcopenia market faces several restraints and challenges that can hinder its growth. One significant barrier is the high cost of branded medications, such as Soolantra and Oracea, which limits affordability and access for many patients, particularly in low-income or uninsured populations.

The global sarcopenia market is primarily driven by the accelerating growth of the aging population, which significantly increases the prevalence of muscle-wasting conditions worldwide. As the number of individuals aged 60 and above continues to rise, particularly in developed and emerging economies, the demand for sarcopenia diagnosis and treatment is expanding rapidly. Additionally, advancements in diagnostic tools-such as handgrip strength assessments, gait speed testing, and imaging techniques like DXA (dual-energy X-ray absorptiometry)-have improved the ability to detect sarcopenia at earlier stages. This heightened clinical awareness has led to more frequent identification of the condition, promoting timely interventions. Furthermore, the market is witnessing robust progress in therapeutic innovation, especially in the development of hormonal treatments like testosterone replacement and biologics targeting muscle anabolic pathways, such as myostatin inhibitors and selective androgen receptor modulators (SARMs). These advancements offer promising avenues for more effective and targeted management of sarcopenia in aging populations.

The growth of the global sarcopenia market is constrained by several critical challenges, foremost among them being the lack of a universally accepted diagnostic standard. Variations in diagnostic criteria-such as those proposed by EWGSOP, AWGS, and other regional bodies-lead to inconsistencies in identifying and classifying sarcopenia, hindering large-scale clinical research, regulatory approval, and treatment standardization. Additionally, limited insurance coverage and reimbursement for sarcopenia-related therapies, particularly nutritional supplements and non-pharmaceutical interventions, restrict patient access and discourage provider adoption.

The competitive landscape of the global sarcopenia market is evolving swiftly, fueled by advancements in therapeutic innovation, strategic partnerships, and an expanding focus on aging-related healthcare. Leading players such as Nestle Health Science, Abbott Laboratories, Biophytis, MyoPax GmbH, and Lipocine Inc. are actively investing in research and development to address the multifactorial nature of sarcopenia. These efforts include the development of targeted therapies such as selective androgen receptor modulators (SARMs), myostatin inhibitors, regenerative stem cell treatments, and advanced nutritional formulations enriched with protein, creatine, and omega-3 fatty acids. Companies are also leveraging digital health tools-including remote monitoring apps, telehealth platforms, and AI-driven diagnostic aids-to enhance patient engagement and adherence. Concurrently, there is a growing emphasis on formulating personalized and combination therapies that integrate pharmaceutical, nutritional, and physical interventions. This innovation-centric, multidisciplinary approach is reshaping the sarcopenia market landscape with a focus on efficacy, long-term functionality, and improved quality of life for the aging global population.

The global sarcopenia market presents significant opportunities driven by emerging healthcare trends and technological advancements. Rapid urbanization, improving healthcare infrastructure, and growing geriatric populations in emerging economies-particularly across Asia-Pacific and Latin America-are opening new avenues for market expansion. These regions are increasingly adopting preventive and therapeutic solutions for age-related conditions, creating untapped potential for sarcopenia interventions. At the forefront of innovation, companies are exploring regenerative medicine and stem cell-based therapies, such as those developed by MyoPax GmbH and Turn Biotechnologies, which aim to restore muscle function and reverse muscle degeneration at the cellular level. Additionally, the integration of digital health tools-including wearable devices, telemedicine platforms, and AI-enabled muscle monitoring apps-is enhancing early diagnosis, patient engagement, and long-term disease management. Together, these advancements are reshaping the sarcopenia landscape by promoting personalized, accessible, and tech-enabled care for aging populations worldwide.

Market Segmentation:

Segmentation 1: by Treatment Class

  • Nutritional Supplements
    • Protein Supplements (Whey, Casein, Collagen)
    • Amino-Acid Supplements (Leucine, HMB, Creatine)
    • Vitamin D and Calcium Supplements
    • Vitamin B12 and Folate Supplements
    • Omega-3 Fatty-Acid Supplements
  • Pharmaceuticals
    • Hormone-Replacement Therapy (Testosterone & Analogues)
    • ACE Inhibitors and Angiotensin II Receptor Blockers
    • Others (Growth-Hormone Secretagogues)
  • Combination Therapies

Segmentation 2: by Route of Administration

  • Oral
  • Parenteral
  • Transdermal / Topical

Segmentation 3: by Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Segmentation 4: by the Region

  • North America
  • Europe
  • Asia-Pacific

The sarcopenia market is witnessing transformative trends that are reshaping its research, development, and delivery landscape. One notable trend is the increasing adoption of artificial intelligence (AI) in drug discovery where companies are using advanced algorithms to identify novel therapeutic targets and accelerate the development of precision treatments for muscle wasting. This technological integration is reducing time-to-market and enabling more targeted, cost-effective drug development. Simultaneously, there is a growing preference for combination therapy approaches that integrate pharmaceutical agents with nutritional supplements and physical therapy to achieve synergistic effects in improving muscle mass and function. These multi-modal strategies are gaining clinical support and improving patient outcomes.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Sarcopenia Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Value chain Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Market Dynamics
    • 1.5.1 Overview
    • 1.5.2 Market Drivers
    • 1.5.3 Market Restraints
    • 1.5.4 Market Opportunities

2. Global Sarcopenia Market (by Treatment Class), Value ($million), 2023-2035

  • 2.1 Nutritional Supplements
    • 2.1.1 Protein Supplements (Whey, Casein, Collagen)
    • 2.1.2 Amino-Acid Supplements (Leucine, HMB, Creatine)
    • 2.1.3 Vitamin D and Calcium Supplements
    • 2.1.4 Vitamin B12 and Folate Supplements
    • 2.1.5 Omega-3 Fatty-Acid Supplements
  • 2.2 Pharmaceuticals
    • 2.2.1 Hormone-Replacement Therapy (Testosterone & Analogues)
    • 2.2.2 ACE Inhibitors and Angiotensin II Receptor Blockers
    • 2.2.3 Others (Growth-Hormone Secretagogues)
  • 2.3 Combination Therapies

3. Global Sarcopenia Market (by Route of Administration), Value ($million), 2023-2035

  • 3.1 Oral
  • 3.2 Parenteral
  • 3.3 Transdermal / Topical

4. Global Sarcopenia Market (by Distribution Channel, Value ($million), 2023-2035

  • 4.1 Hospitals Pharmacies
  • 4.2 Retail Pharmacies
  • 4.3 Online Pharmacies
  • 4.4 Others

5. Global Sarcopenia Market (by Region), Value ($Million), 2023-2035

  • 5.1 North America
    • 5.1.1 Market Dynamics
    • 5.1.2 Market Sizing and Forecast
    • 5.1.3 North America Sarcopenia Market, by Country ($Million), 2023-2035
      • 5.1.3.1 U.S.
      • 5.1.3.2 Canada
  • 5.2 Europe
    • 5.2.1 Market Dynamics
    • 5.2.2 Market Sizing and Forecast
    • 5.2.3 Europe Sarcopenia Market, by Country ($Million), 2023-2035
      • 5.2.3.1 U.K.
      • 5.2.3.2 France
      • 5.2.3.3 Germany
      • 5.2.3.4 Rest-of-Europe
  • 5.3 Asia-Pacific
    • 5.3.1 Market Dynamics
    • 5.3.2 Market Sizing and Forecast
    • 5.3.3 Asia-Pacific Sarcopenia Market, by Country ($Million), 2023-2035
      • 5.3.3.1 Japan
      • 5.3.3.2 China
      • 5.3.3.3 India
      • 5.3.3.4 Rest-of-Asia-Pacific
  • 5.4 Rest-of-the-World
    • 5.4.1 Market Dynamics
    • 5.4.2 Market Sizing and Forecast
    • 5.4.3 Rest-of-the-World Sarcopenia Market, by Country ($Million), 2023-2035
      • 5.4.3.1 Latin America
      • 5.4.3.2 Middle East and Africa

6. Global Sarcopenia Market Competitive Landscape and Company Profiles

  • 6.1 Competitive Landscape
    • 6.1.1 Mergers and Acquisitions
    • 6.1.2 Partnership, Alliances and Business Expansion
    • 6.1.3 New Offerings
    • 6.1.4 Regulatory Activities
    • 6.1.5 Funding Activities
  • 6.2 Company Profiles
    • 6.2.1 Nestle Health Science
      • 6.2.1.1 Overview
      • 6.2.1.2 Top Products / Product Portfolio
      • 6.2.1.3 Top Competitors
      • 6.2.1.4 Target Customers/End-Users
      • 6.2.1.5 Key Personnel
      • 6.2.1.6 Analyst View
    • 6.2.2 Abbott Laboratories
      • 6.2.2.1 Overview
      • 6.2.2.2 Top Products / Product Portfolio
      • 6.2.2.3 Top Competitors
      • 6.2.2.4 Target Customers/End-Users
      • 6.2.2.5 Key Personnel
      • 6.2.2.6 Analyst View
    • 6.2.3 Bayer AG
      • 6.2.3.1 Overview
      • 6.2.3.2 Top Products / Product Portfolio
      • 6.2.3.3 Top Competitors
      • 6.2.3.4 Target Customers/End-Users
      • 6.2.3.5 Key Personnel
      • 6.2.3.6 Analyst View
    • 6.2.4 Sanofi S.A.
      • 6.2.4.1 Overview
      • 6.2.4.2 Top Products / Product Portfolio
      • 6.2.4.3 Top Competitors
      • 6.2.4.4 Target Customers/End-Users
      • 6.2.4.5 Key Personnel
      • 6.2.4.6 Analyst View
    • 6.2.5 Novartis AG
      • 6.2.5.1 Overview
      • 6.2.5.2 Top Products / Product Portfolio
      • 6.2.5.3 Top Competitors
      • 6.2.5.4 Target Customers/End-Users
      • 6.2.5.5 Key Personnel
      • 6.2.5.6 Analyst View
    • 6.2.6 Eli Lilly and Company
      • 6.2.6.1 Overview
      • 6.2.6.2 Top Products / Product Portfolio
      • 6.2.6.3 Top Competitors
      • 6.2.6.4 Target Customers/End-Users
      • 6.2.6.5 Key Personnel
      • 6.2.6.6 Analyst View
    • 6.2.7 MyoPax GmbH
      • 6.2.7.1 Overview
      • 6.2.7.2 Top Products / Product Portfolio
      • 6.2.7.3 Top Competitors
      • 6.2.7.4 Target Customers/End-Users
      • 6.2.7.5 Key Personnel
      • 6.2.7.6 Analyst View
    • 6.2.8 Amgen Inc.
      • 6.2.8.1 Overview
      • 6.2.8.2 Top Products / Product Portfolio
      • 6.2.8.3 Top Competitors
      • 6.2.8.4 Target Customers/End-Users
      • 6.2.8.5 Key Personnel
      • 6.2.8.6 Analyst View
    • 6.2.9 Pfizer Inc
      • 6.2.9.1 Overview
      • 6.2.9.2 Top Products / Product Portfolio
      • 6.2.9.3 Top Competitors
      • 6.2.9.4 Target Customers/End-Users
      • 6.2.9.5 Key Personnel
      • 6.2.9.6 Analyst View
    • 6.2.10 GlaxoSmithKline plc
      • 6.2.10.1 Overview
      • 6.2.10.2 Top Products / Product Portfolio
      • 6.2.10.3 Top Competitors
      • 6.2.10.4 Target Customers/End-Users
      • 6.2.10.5 Key Personnel
      • 6.2.10.6 Analyst View
    • 6.2.11 Others

7. Research Methodology

List of Figures

  • Figure: Sarcopenia Market (by Scenario), $Million, 2024, 2028, and 2035
  • Figure: Global Sarcopenia Market, 2024 and 2035
  • Figure: Global Sarcopenia Market Key Trends, Impact Analysis, 2023-2035
  • Figure: North America Sarcopenia Market, $Million, 2023-2035
  • Figure: Europe Sarcopenia Market, $Million, 2023-2035
  • Figure: Asia-Pacific Sarcopenia Market, $Million, 2023-2035
  • Figure: Rest of the World Sarcopenia Market, $Million, 2023-2035

List of Tables

  • Table: Market Snapshot
  • Table: Global Sarcopenia Market (by Treatment Class), $Million, 2023-2035
  • Table: Global Sarcopenia Market (by Route of Administration), $Million, 2023-2035
  • Table: Global Sarcopenia Market (by Distribution Channel), $Million, 2023-2035
  • Table: Global Sarcopenia Market (by Region), $Million, 2023-2035